|
|
||||
        
|
Cellceutix Corporation (CTIX)
|
|||
|
Monday, May 2, 2011 – After Market Close Green Baron New “Stock Pick”
Cellceutix Corporation (OTCQB: CTIX – $.90 per share) Common Shares Outstanding / 91,914,500 Market Cap / $82.72 million 52-Week High / $1.00 52-Week Low / $.10 Average Price / $.75 (50-day) .46 (200-day) Cellceutix Novel Cancer Drug Kevetrin™ Gains Attention from Big Pharma Compound Seen As a Breakthrough Could See Extreme Fast-Track to Approval if Human Tests Confirm Results (Find out why); Cellceutix on Target to File IND for Kevetrin in May CEO of Cellceutix, Leo Ehrlich: "It is often times difficult to explain the magnitude of the potential of Kevetrin™” Dr. Sylvia Holden: "The manner in which people gravitated to Cellceutix to learn about Kevetrin and its p53 breakthroughs attests to the value of Kevetrin as a novel cancer therapy.” Green Baron’s Chooses CTIX to be 95th “Stock Pick” Since Inception; The Upside for this Stock is Staggering! Over the years, we at The Green Baron Report have resisted the temptation to introduce our loyal members to biotech stocks. Prior to acting as Editor in Chief of The Green Baron Report for the past ten years, I was a licensed stockbroker for over twelve years and focused a great deal of my attention on the biotech and pharmaceutical industry. I clearly understand the glorified potential of hitting it big with a blockbuster drug, but I also understand the grueling process it takes to achieve that success and the disappointment should key milestones remain unmet. It was not until I read a 10-page independently written blog that summarizes the history and direction of Cellceutix that I considered that The Green Baron Report should bring this stock to the attention of our subscribers. I needed to be sure that everything in this report was accurate and true. We have now confirmed that all details in the report are accurate. Along with the following report of our own, we are also providing the 10-page report that caught our interest. To view, please click: The Green Baron Report is officially making Cellceutix Corporation (OTCQB: CTIX) our 95th Green Baron “Stock Pick” since inception. Results compiled from the most recent trade prior to dissemination of this report to the subsequent high will be closely monitored at www.thegreenbaron.com and through email updates to members. We have very aggressive price projections for CTIX and believe the stock has huge upside potential based on several positive fundamental and technical factors. TRADER’S NOTES: CTIX has experienced a volume surge over the past ten trading days that indicates accumulation by investors in the know. Since April 15, CTIX has traded at prices between .79 and $1.00 on average volume of 77,520 shares. There has been more buying at these prices in the past ten trading days than in total over the previous three months. Bid support is currently very strong at .85 per share and is represented at this level by multiple market makers. “Cellceutix offers investors one of the greatest potential risk/reward ratios from publicly listed companies– one would be hard-pressed to find a company that offers that kind of opportunity.” – CEO of Cellceutix, Leo Ehrlich Cellceutix owns the rights to eight drug compounds, including Kevetrin, which it is developing as a treatment for cancers; KM-133, for the treatment of psoriasis; and KM-391, for the treatment of autism. Cellceutix recently announced that research on KevetrinTM, the Company's flagship compound against cancers, has demonstrated the potential for a major breakthrough in cancer research by exhibiting an activation of p53. p53, often referred to as the "Guardian Angel Gene" or the "Guardian Angel of the Human Genome" due its crucial role in controlling cell mutations, is a tumor suppressor protein that is encoded by the TP53 gene in humans and has been widely regarded as possibly holding a key to the future of cancer therapies. In more than 50 percent of all human carcinomas, p53 is limited in its anti-tumor activities by mutations in the protein itself. Currently, there are greater than 10 million people with tumors that contain inactivated p53, while a similar number have tumors in which the p53 pathway is partially abrogated by inactivation of other signaling components. This has left cancer researchers with the grand challenge of searching for therapies that could restore the protein's protective function, which Kevetrin appears to be doing the majority of the time. Kevetrin has been shown to reactivate P53, often to baseline status, which, in turn, activates other proteins that destroy or significantly slow the growth of cancer cells. This is something that scientists worldwide, at pharmaceutical companies both large and small, have been striving for, but to the best of our knowledge, have not yet achieved. The Green Baron Report believes that CTIX stock is going to continue to see increased activity and accumulation. As more investors gain an understanding of the potential value of Cellceutix, we believe it will continue to rise in price. Here are several reasons we would own CTIX and some developments that could cause the stock to gain many times the current price: · Filing of IND for Kevetrin in May – Through its use of Kevetrin™, Cellceutix is attacking cancers that all other drugs have failed against. Assuming the FDA has no objections to beginning human trials, it would be a huge milestone achievement for the Company. · Proof of Efficacy Early On, Fast-Track to Approval – Normal phase 1 trials test on healthy volunteers and test primarily for safety. Cancer trial drugs are often given to Stage 4 terminally ill patients who usually have cancers that are already resistant to all existing therapies. Since these are the patients Cellceutix is anxious to treat, positive results could springboard development to fast-track status. Additionally, Kevetrin is novel and non-toxic. · Increased Big Pharma Interest in Kevetrin and Autism Drug – Cellceutix disclosed on March 8, 2011 that it entered into a Confidential Disclosure Agreement (CDA) pertaining to its anti-cancer drug, Kevetrin™ with one of the world's largest pharmaceutical companies. It's relatively uncommon for big pharma to be signing a CDA on a compound before clinical trials are underway. On March 28 it also entered into a CDA pertaining to KM-391, its novel compound being developed as a treatment for autism, with a multi-billion dollar pharmaceutical company. In a recent interview, the CEO stated that they are in correspondence with top five pharmas. · Proven Management – Among its leadership, President Dr. Krishna Menon received the President’s Award during his time as a Research Associate at Eli Lilly for his instrumental role in choosing Alimta and Gemzar for development as cancer therapies. These blockbuster chemotherapies are still two of the most widely used drugs today and generated more than $3.3 billion in sales last year alone. Scientific Advisory Board Member Dr. Emil Frei is widely regarded as one of the world’s leading oncologists with more than 40 years’ experience including being former Physician-in-Chief at the Dana-Farber Cancer Institute. Scientific Advisory Board Member Dr. Samuel Danishefsky is widely regarded as one of the world's leading chemists in cancer research · Location for Trials – It is possible that trials for Kevetrin will be held at one of the world’s most prominent cancer centers in the world. This would further lend to the credibility and interest in its results. · Market Size for Autism Drug and Compound to Treat Psoriasis – It’s obvious that a novel treatment for cancer could easily generate billions in sales each year. Cellceutix has a compound it has developed for autism, not merely the symptoms but the underlying cause. Potential sales for an approved drug in this market could be $10 billion or more. A third compound to treat psoriasis in development would go after a market of about $1 billion. We encourage members to read all about Cellceutix and get to know why this company truly has the potential to be the next biotechnology success. It is important to gain an understanding about the history of p53 and why the recent breakthroughs generated from Kevetrin studies are causing big pharma to take a serious look at Cellceutix. We are confident you will come away with the same conclusion we have and make perfect sense that you add CTIX to your portfolio. About Cellceutix Corporation Cellceutix Corporation is presently a preclinical drug developer. Cellceutix owns the rights to eight drug compounds, including Kevetrin, which it is developing as a treatment for cancers; KM-133, for the treatment of psoriasis; and KM-391, for the treatment of autism. More information is available on the Cellceutix web site at www.cellceutix.com. Kevetrin – Lead Compound Kevetrin, its lead product candidate, is a small molecule compound proprietary to the Company. Its structure is distinct from other anti-cancer agents currently on the market. Kevetrin was discovered by the Company's founder, Dr. Krishna Menon, and has been studied extensively (in vitro and in vivo) demonstrating potent anti-cancer activity against various cancer cell lines. Kevetrin's recent success in a series of animal model experiments with drug-resistant cancer cell lines has galvanized the Company to focus on Kevetrin's development potential in this area. Some highlights of the studies conducted to date include: · Small molecule drug that is structurally different from anti-cancer agents currently on the market · In vitro cytotoxicity is less than paclitaxel but tumor growth reduction is greater in models of drug resistant lung, breast and colon cancer · Demonstrated success in more than 5,000 small animal tests, achieving significant delays in tumor growth compared to controls in breast, prostate and colon cancer tumors. · In animal tests of a head and neck cancer cell line, delay in tumor growth was significantly increased by 14 days with Kevetrin alone (about the same as with radiation alone) but when Kevetrin was administered in conjunction with radiation, tumor growth delay increased by 36 days, more than two-fold compared to controls · In small animal tests, Kevetrin was well tolerated.
Chemistry Kevetrin is a small molecule that is different in structure from all currently marketed cancer drugs. It is water-soluble and simple to synthesize from commercially available starting materials. We expect that it will initially be administered as an intravenous (IV) product. Patent Protection Cellceutix filed a patent application covering Kevetrin in May, 2009. The patent application claims pharmaceutical formulations of Kevetrin in addition to novel compounds having similar structures to Kevetrin that may have potential as drug development candidates. The application also covers the use of Kevetrin and the other compounds in various disease states, including cancers. Cellceutix plans to file patent applications in other countries within a year of the U.S. filing. Kevetrin in vitro studies In vitro studies have shown that Kevetrin is less cytotoxic than paclitaxel, yet has more potent anti-tumor activity against a range of drug resistant cancer cell lines. This indicates that Kevetrin is not acting primarily as a cytotoxic agent. Kevetrin Pharmacokinetics In mice, Kevetrin showed a biphasic time vs. drug concentration curve with an elimination half-life of about 2.2 hours.
Drug-Resistant Cancer Cell Lines Lung Cancer
Kevetrin has been studied in animal models using a
number of drug-resistant cell lines. Kevetrin was
studied in two cell lines of multi-drug resistant
lung cancer. In two studies with the A549 cell
line, Kevetrin showed average tumor growth delay of
72% and average tumor volume reduction of 81%
compared to controls. Both tumor growth delay and
tumor volume reduction were also significantly
greater with Kevetrin than with paclitaxel (Taxol)
(p<0.001). Breast Cancer In tests on two multi-drug resistant non-small-cell lung carcinoma human cell lines, A549 and NCI-H1975 -in each cell line- tumor volume was reduced by more than 90% and tumor growth was delayed by more than 100%. In addition, both the tumor volume reduction and the tumor growth delay were greater in each cell line with Kevetrin than with paclitaxel (brand name Taxol) (p<0.01). In animal model testing on a taxane-resistant, estrogen receptor-negative breast cancer human cell line, MDA-MB-435s, tumor volume was reduced by 72% and tumor growth was delayed by more than 52% with Kevetrin when compared with paclitaxel (Taxol) (p<0.01) or with cisplatin (p<0.01). Colon Cancer Kevetrin showed tumor growth delay of 43% compared to controls and paclitaxel when tested on animals with HCT-15 P-glycoprotein drug resistant colon cancer.
Head and Neck Cancer
Colon Cancer
Breast Cancer
Prostate Cancer Summary Kevetrin is a small molecule easily synthesized from commercially available starting materials. A patent application has been filed covering pharmaceutical formulations and uses of Kevetrin. Kevetrin has been extensively studied in animal models of cancer, including several drug-resistant cell lines. It has consistently shown activity as good as or better than standard therapies. In drug-resistant cell lines, Kevetrin has shown excellent activity, indicating potential for development as a treatment for drug-resistant cancers. Kevetrin has generally been well tolerated by the test animals, as evidenced by weight loss of less than 10% in all studies. GLP toxicity studies are ongoing. Recent Key Press Releases Monday, April 25, 2011 - Cellceutix Cancer Drug Trumps Competitors – Kevetrin™ Stands Out in Its Mechanism of Action by Activating Both Transcription - Dependent and Transcription-Independent Pathways to Promote Apoptosis in a Non-Genotoxic Manner and Targets Both Mutated and Wild Type p53 – BEVERLY, Mass., - Cellceutix Corporation (Pinksheets: CTIX) (OTC.BB: CTIX), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat unmet medical conditions including drug-resistant cancers, announced that at the 102nd annual American Association for Cancer Research (AACR) meeting held in Orlando, FL, April 2nd to 6th, four posters described new compounds that directly affected p53 function. p53, also known as the "Guardian Angel of the human genome" due to its crucial role in controlling cell mutations, is a tumor suppressor protein that is encoded by the TP53 gene in humans and has been widely regarded as possibly holding a key to the future of cancer therapies. Aside from Cellceutix's compound, Kevetrin™, none of the other three compounds demonstrated success against a broad spectrum of cancers. Compound A and Compound B, reported by Wang, et al, (Ascenta Therapeutics, Abstract #LB-204) and MI-63 reported by Scott et al, (Abstract #4507) showed efficacy in tumors limited to wild type p53. Pernaza et al, (Abstract #3242) reported that compound E12/DP13-117 was also "expected to work" on tumors containing only wild type p53. These novel compounds only affect tumors with wild type p53. Kevetrin™ affects both wild type and mutant p53 by modulating E3 ligase processivity, a unique mechanism of action which distinguishes it from the other three drugs. CEO of Cellceutix, Leo Ehrlich, commented, "It is often times difficult to explain the magnitude of the potential of Kevetrin™. Compounds that affect only wild type p53 address only a fraction of the tumors that Kevetrin™ has the potential to treat. This past June, an emerging biopharmaceutical company announced they had signed an agreement with a major pharmaceutical company covering early-stage agents being investigated for their potential to restore tumor cell apoptosis related to p53. Per the announcement, milestone payments could reach approximately $400 million in addition to royalties from sales. It seems that that compound is also at an earlier stage of development than ours. Considering that Kevetrin could potentially address double the number of cancer patients with either mutated or wild type p53, I would expect Kevetrin™ to have a value significantly greater than that." Monday, April 18, 2011 - Cellceutix CEO, Leo Ehrlich, Conducts Interview with "Biotech Stock Trader"; Dr. Paul Ginsberg, (Renowned Patent Attorney) Joins Cellceutix Advisory Board - Cellceutix Corporation, a biopharmaceutical company focused on discovering and developing small molecule drugs to treat unmet medical conditions including drug-resistant cancers, is pleased to announce that its CEO Leo Ehrlich has conducted an interview with Biotech Stock Trader, a news and information portal for investors in pharmaceutical and biotechnology firms. The interview provides additional insight into Cellceutix, the future path of the Company, and its business model. The company's potential and developments are discussed as well as the Cellceutix pipeline, upcoming clinical trials, and the Company's potential revolutionary cancer medication breakthrough with Kevetrin™ to reactivate p53, the "Guardian Angel of the Human Genome." The interview is available for viewing on the Cellceutix website at http://www.cellceutix.com/news/BiotechStockTrader.html and at http://biotechstocktrader.com/cellceutix-otcqb-ctix... Cellceutix also is pleased to announce that they have added renowned patent attorney, Dr. Paul Ginsberg, to their Advisory Board. Cellceutix CEO Leo Ehrlich commented, "We are excited that Dr. Ginsberg wanted to expand his relationship with Cellceutix. Dr. Ginsberg has already been of great help in the patent process of Kevetrin™ and we look forward to his knowledge and experience as we finalize the patent application for our autism drug. Dr. Ginsberg, with his in depth understanding of pharmaceutical chemistry, is a perfect fit to join our other amazing scientific advisors who have been of such enormous help to our early and extraordinary scientific successes. " Commenting on joining the Cellceutix Advisory Board, Dr. Ginsburg stated, "I have been working closely with Cellceutix and Dr. Menon for some time now and based on my past experience in the field, I see great potential in the Company. I am both pleased and excited to join the exceptional Cellceutix team and look forward to what the future may hold with not only Kevetrin™, but KM-391 for autism and other drugs in the pipeline which I have gotten to know quite well." About Dr. Ginsberg Dr. Ginsburg received his Ph.D. in Chemistry from the City University of New York and his law degree from Columbia University where he was a Harlan Fiske Stone Scholar. He was elected to Phi Beta Kappa at the City College of New York and to the scientific research honor society Sigma Xi at CUNY. Dr. Ginsburg has spent most of his career as corporate counsel representing large and small pharmaceutical, biotechnology, chemical and consumer products companies. His last position was at Pfizer Inc., where he served as Head of the New York Patent Department which dealt with several blockbuster products, including Viagra and Chantix. He represented Pfizer on the intellectual property committees of the National Association of Manufacturers, the Chemical Manufacturers Association and the Biotechnology Industry Organization. Dr. Ginsburg has lectured widely on pharmaceutical and biotechnology patent prosecution and licensing at the Practicing Law Institute and Columbia Law School . Prior to his twenty year career at Pfizer, Dr. Ginsburg was a senior attorney at Schering-Plough. He was subsequently recruited by Merck and then by the highly respected IP law firm, Fish & Neave. Dr. Ginsburg is perhaps most well-known as the author of the patent covering Schering-Plough's hugely successful product Claritin. He also authored important patents covering Schering-Plough's highly successful alpha-interferon product. Dr. Ginsburg has authored the patent application for Cellceutix anticancer product Kevetrin™, which has been filed in the United States and other countries and has advised Cellceutix on patent and licensing matters during the past few years. Monday, April 11, 2011 - Cellceutix Poster Presentation on its p53 Cancer Breakthrough Attracts Wide Interest at 102nd AACR Meeting - Cellceutix Corporation (OTCQB: CTIX) is pleased to announce that their recent poster at the 102nd Annual Meeting of the American Association for Cancer Research (AACR) generated significant interest from major Pharmaceutical companies and numerous investigators. The poster, entitled, "Kevetrin™, A Novel Small Molecule, Activates p53, Enhances Expression of p21, Induces Cell Cycle Arrest and Apoptosis in a Human Cancer Cell Line" was showcased by Cellceutix at the AACR Meeting held April 2-6, 2011 in Orlando, FL. The poster is available for viewing on www.cellceutix.com. Cellceutix was represented by its Chief Scientific Officer, Dr. Krishna Menon, and two of its scientific consultants, Dr. Ashok Kumar and Dr. Sylvia A. Holden. Dr. Holden received her PhD from Boston University followed by an NIH-funded post-doctoral fellowship at Dana-Farber Cancer Institute in the Division of Cancer Pharmacology headed by chemotherapy pioneer and Cellceutix Scientific Advisor, Dr. Emil Frei III. Before joining Cellceutix, Dr. Holden was the Director of Pharmacology at EMD Serono in Billerica, MA (Merck KGaA) and Director of Tumor Biology at Shionogi BioResearch Corp., in Lexington, MA (presently Synta Pharmaceuticals). She was awarded 5 US patents and has published over 100 publications in peer-reviewed journals, including 12 first-authored papers and publications in Science and Nature Medicine. Commenting on the poster session, Dr. Holden stated, "I have been participating in the AACR annual meeting for more than twenty years and I can't recall a poster session ever being as active as Cellceutix's was this year. There were people waiting at our poster before we had arrived and a steady flow of elite scientists at all times up to and through the closing of the session." Dr. Holden continued, "The manner in which people gravitated to Cellceutix to learn about Kevetrin and its p53 breakthroughs attests to the value of Kevetrin as a novel cancer therapy. We were approached for in-depth conversations by representatives of the world's largest pharmaceutical companies and most prestigious universities in the United States. Moreover, we held a meeting with the National Cancer Institute to discuss the future for Kevetrin development as well. Now that people have gotten a first-hand look at our research explaining the mechanism of action for Kevetrin, the interest that was starting to brew is truly intensifying as organizations of all sizes want to continue discussions back at our offices and lab." Additionally, the Cellceutix team was proud that once again during this year's convention, Cellceutix Scientific Advisor, Dr. Emil Frei III, was honored by the AACR. Dr. Frei was a previous recipient of accolades from the AACR as the inaugural AACR Award for Lifetime Achievement in Cancer Research was given to him in 2004. In 2009, the AACR recognized Cellceutix cancer drug Kevetrin, as an elite drug in development due to promising potency during its first "Frontiers in Basic Cancer Research Meeting." Thursday, March 31, 2011 - Cellceutix Cancer Drug, Kevetrin, Shows Increased Levels of p21; Biomarker for Cancer Trials - Cellceutix Corporation is pleased to announce that additional research has been concluded on Kevetrin™, the Company's flagship cancer compound. Kevetrin was shown to increase levels of p21, a key protein responsible for cell cycle arrest, in the lymphocytes of mice. Cellceutix will be incorporating the p21 assay into its Investigational New Drug application scheduled to be filed with the Food and Drug Administration in approximately six weeks (May 2011). If the data are duplicated in human studies, p21 as a biomarker will be another major step forward in cancer research for Kevetrin™, which has already been shown to be a non-genotoxic drug that reactivates p53; a major development of its own. Dr. Krishna Menon, Chief Scientific Officer for Cellceutix, commented, "There has been a big movement in oncology research to establish new biomarkers as they are an earlier measure of activity in the body's cells. p21 has been proven to play a critical role in cell cycle arrest leading to cell death. No one has been able to validate it as a biomarker, to the best of our knowledge, so this will be a major event not only for Cellceutix, but for the cancer clinical trials." Dr. Menon continued, "Increased levels of p21 are not only a predictor of cell death, but a benchmark in judging effectiveness of Kevetrin™. Our pre-clinical research on p21 has met its endpoints and we are optimistic that the upcoming human trials will yield similar results." Monday, March 28, 2011 - Cellceutix Announces that it has Signed Confidential Disclosure Agreement for its Autism Drug with Large Pharmaceutical Company - Cellceutix Corporation today disclosed that it has entered into a Confidential Disclosure Agreement (CDA) pertaining to KM-391, its novel compound being developed as a treatment for autism, with a multi-billion dollar pharmaceutical company. Cellceutix will be providing shareholders updates on the latest developments with KM-391 in the near future. Cellceutix CEO, Leo Ehrlich, commented, "This is simply another vote of confidence from large pharma as to the strength of our pipeline and a testament to the attention that we are receiving on a global level." Mr. Ehrlich continued, "While signing a CDA does not imply or guarantee that a licensing deal or any other transaction will ever happen, it is important in the sense of industry recognition of our compounds, as the signing of a CDA this early in development is generally a very rare occurrence." Additionally, Cellceutix has been informed by Formatech, its formulation manufacturer, that production has been completed on Kevetrin™ for use in clinical trials. The Company is still on schedule for filing its IND with the FDA in May 2011. Kevetrin™ is Cellceutix's breakthrough compound targeting lung, breast, colon and other cancers not responding to existing drug therapies. Monday, March 14, 2011 - Cellceutix Reports Production of Its Anti-Cancer Drug Kevetrin Has Begun - CEO Comments on Clinical Process and Believes "The Best Is Yet to Come" - Cellceutix Corporation is pleased to announce that Kevetrin™, the Company's flagship compound for the potential treatment of cancers not responding to existing drugs (drug-resistant cancers), has begun production for clinical trials. This was confirmed by Formatech Inc.( Andover , MA) which formulates developmental medications for clinical trials. "We appreciate being given the opportunity to develop and manufacture Kevetrin™, Cellceutix's first clinical candidate," said Indu Javeri, Ph.D., CEO of Formatech. "We have worked closely with Dr. Menon and his team at Cellceutix over the recent months and we look forward to encouraging results from their clinical trials. We understand that Kevetrin has a unique mechanism of action that could dramatically impact the treatment of multiple cancers. In an industry that produces very few truly novel products, it is refreshing to see a new potential chemotherapy compound like Kevetrin™." Leo Ehrlich, CEO of Cellceutix, commented, "We are thrilled that the production process is underway. I very much appreciate Dr. Javeri's comments." Mr. Ehrlich continued, "Our lead compound Kevetrin™ is moving forward, and rapidly garnering attention. People are now realizing the results and potential of our hard work. Kevetrin™ has a unique chemical structure; the first in its class of chemistry to be used as an anti-cancer agent. Our preclinical testing results were beyond our best expectations against drug-resistant cancers. Most important of all was the discovery of the p53--Guardian angel--mechanism of action. These factors are quite important as we move towards clinical trials. Should we achieve proper efficacy during the planned clinical trials, we hope that the FDA may grant Accelerated Approval or Priority Review for Kevetrin™. While there are no assurances of success in biotechnology research, at Cellceutix we are enthusiastic about what has been achieved thus far, and believe the best is yet to come." Accelerated Approval or Priority Review programs by the FDA programs were put into effect approximately twenty years ago specifically for new drugs that provide the best opportunity for a viable therapy in an area of unmet medical need. In these cases, it is to the advantage of all involved to get these compounds to late-stage clinical trials quickly, without sacrificing any safety. Cellceutix is currently finalizing and reviewing all Investigational New Drug (IND) documentation for submission to the United States Food and Drug Administration, in May 2011. Tuesday, March 8, 2011 - Cellceutix Reports Confidential Disclosure Agreement Signed With Major Pharmaceutical Company - Company Developing New Chemotherapy Drug Kevetrin to Treat Cancers Not Responding to Existing Drugs - Cellceutix Corporation today disclosed that it has entered into a Confidential Disclosure Agreement (CDA) pertaining to its anti-cancer drug, Kevetrin™, with one of the world's largest pharmaceutical companies. Cellceutix CEO, Leo Ehrlich, commented, "It's relatively uncommon for big pharma to be signing a CDA on a compound before clinical trials are underway. The process begins with Cellceutix providing non-confidential information to the other party. If after review of the materials the interest remains high, they will request to enter into a CDA. We are glad that their interpretation of the Kevetrin™ studies was sufficient to warrant entering into a CDA with Cellceutix." Mr. Ehrlich continued, "Signing a CDA does not mean a licensing deal or other transaction is imminent and makes no assumptions that it ever will. But, conversely, a deal won't ever happen without first signing a CDA. At Cellceutix, we are focused on moving our compounds toward clinical trials and maximizing shareholders' value. This agreement is one more step in that process." Cellceutix has previously reported that in animal studies Kevetrin™ has shown potent anti-tumor activity against many different cancers including lung, breast and colon cancers as well as leukemia and various strains for which current drugs are ineffective ("drug-resistant cancers"). Data released over the last week by Cellceutix has also shown that Kevetrin™ demonstrates characteristics that are seen as highly desirable in a new chemotherapy as it has not only shown to be non-genotoxic, but also reactivates p53, the "Guardian Angel Protein." Management
President, Chief Scientific Officer, Board of
Directors - Dr. Krishna Menon Chief Executive Officer and CFO, Board of Directors- Leo Ehrlich, CPA A founder of Cellceutix, he has served as Chief Financial Officer (CFO) and Director since inception in June 2007 and as CEO since November 2010. From 1999 to December 2007, Mr. Ehrlich had been a director at StatSure Diagnostic Systems, Inc. and has held different executive officer positions at that company including CEO, President and CFO. Mr. Ehrlich was also was a founder, CFO and director at Nanoviricides, Inc. from June 1, 2005. until May 2007. Mr. Ehrlich is a Certified Public Accountant and received his BBA from Bernard Baruch College of the City University of New York. Emil Frei III, MD Dr. Frei is one of the world's leading oncologists, a pioneer of chemotherapy and a leader in medical research, clinical practice and education. His distinguished career includes 40 years in top leadership positions such as Chief of Medicine at National Cancer Institute, Associate Scientific Director at M. D. Anderson, and Director and Physician-in-Chief at the Dana-Farber Cancer Institute. He continues as Physician-in-Chief, Emeritus, at Dana-Farber. Dr. Samuel Danishefsky, Scientific Advisor Dr. Samuel Danishefsky is an internationally recognized leader in chemistry, specializing in the synthesis of biologically active organic compounds. He is regarded as one of the world's leading chemists in cancer research. Dr. Danishefsky earned his Ph.D. in chemistry from Harvard. He spent 14 years at Yale University, where he rose to the rank of Sterling Professor of Chemistry, the highest academic rank at Yale University, awarded to a tenured faculty member considered one of the best in his or her field. By 1991, he was also sharing his time with Memorial Sloan-Kettering Cancer Center as director of the Laboratory for Cancer Research Bioorganic Chemistry, becoming chair in 1993. He accepted an appointment as professor at Columbia University in 1993, and now conducts research at both institutions. AWARDS · Shared the distinguished Wolf Award and $100,000 Prize, with Gilbert Stork · American Chemical Society's Guenther Award · Aldrich Award for Creative Work in Synthetic Organic Chemistry · Benjamin Franklin Medal in Chemistry \ · National Academy of Sciences' NAS Award in Chemical Sciences · Cope Medal -- American Chemical Society Green Baron Conclusion We believe Cellceutix is just starting to gain attention from Kevetrin™, its lead compound for treatment of a variety of drug resistant cancers. Big pharma appears to already have keen interest in what actually could be the biggest cancer treatment breakthrough of this century. We recognize it is still early, but excitement generated by some close to the company indicates there is something really big going on here. We encourage investors to do two things. First, read the 10-page report we provided a link to at the beginning of this report. It will really help you understand why discoveries made thus far by the Company are so important. Second, read through the Company’s press releases over the past few months in their entirety and focus on the statements made by veteran management and its advisors. A new, novel treatment for cancer would be considered one of the greatest discoveries to be developed in our lifetime. Cellceutix has a legitimate shot at being the Company behind it. The current market cap represents only a small fraction of what this stock would trade for as it successfully achieves a new milestone. Based on research thus far, we are confident that Cellceutix will prove it has discovered the “Holy Grail” to cancer treatment, or at least a beneficial treatment to a number of challenging cancers. Contact:
Cellceutix Corp.
|
||||
|
. |
||||
